Comparative Pharmacology
Head-to-head clinical analysis: ACTISITE versus DOXY 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTISITE versus DOXY 200.
ACTISITE vs DOXY 200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex, and thus inhibiting peptide chain elongation. It is bacteriostatic and active against a broad range of gram-positive and gram-negative bacteria, as well as atypical organisms.
Topical application of tetracycline hydrochloride 10 mg/g periodontal fiber. Inserted into periodontal pocket and left in place for 10 days.
200 mg orally once daily or 100 mg orally every 12 hours.
None Documented
None Documented
Not applicable due to local degradation; systemic half-life is negligible as tetracycline hydrochloride is not absorbed.
Terminal elimination half-life: 18–22 hours in adults with normal renal function; prolonged in renal impairment (up to 40 hours).
Primarily eliminated by phagocytic degradation at the application site; minimal systemic absorption, negligible renal or biliary excretion.
Renal: 40% unchanged via glomerular filtration; Biliary/fecal: 20–25% as active drug and metabolites; remainder as inactive metabolites.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic